EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

MetAP2 as a Therapeutic Target for Obesity and Type 2 Diabetes: Structural Insights, Mechanistic Roles, and Inhibitor Development

Dong Oh Moon

Biomolecules · 10.12.2024 · 14 (12) · 1572

DOI: 10.3390/biom14121572 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 10.12.2024. Verfasst von Dong Oh Moon. Beteiligte Einrichtung: Department of Biology Education, Daegu University, 201, Daegudae-ro, Gyeongsan-si 38453, Gyeongsangbuk-do, Republic of Korea. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 2 Diabetes Mellitus (T2DM) and obesity are globally prevalent metabolic disorders characterized by insulin resistance, impaired glucose metabolism, and excessive adiposity. Methionine aminopeptidase 2 (MetAP2), an intracellular metalloprotease, has emerged as a promising therapeutic target due to its critical role in regulating lipid metabolism, energy balance, and protein synthesis. This review provides a comprehensive analysis of MetAP2, including its structural characteristics, catalytic mechanism, and functional roles in the pathophysiology of T2DM and obesity. The unique architecture of MetAP2’s active site and its interactions with substrates are examined to elucidate its enzymatic function. The review also explores the development of MetAP2 inhibitors, focusing on their mechanisms of action, preclinical and clinical findings, and therapeutic potential. Special emphasis is placed on docking studies to analyze the binding interactions of six key inhibitors (fumagillin, TNP-470, beloranib, ZGN-1061, indazole, and pyrazolo[4,3-b]indole) with MetAP2, revealing their structural determinants for efficacy and specificity. These findings underscore the potential of MetAP2 as a therapeutic target and provide valuable insights for the rational design of next-generation inhibitors to address obesity and T2DM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2ObesityHumansAnimalsAminopeptidasesMethionyl AminopeptidasesMolecular Docking SimulationO-(Chloroacetylcarbamoyl)fumagillolIndazolesCatalytic DomainMetalloendopeptidasesEnzyme InhibitorsSesquiterpenes

Stichwörter der Autor:innen

MetAP2T2DMinhibitorsobesity

Substanzen

METAP2 protein, humanAminopeptidasesMethionyl Aminopeptidasesmethionine aminopeptidase 2O-(Chloroacetylcarbamoyl)fumagillolIndazolesMetalloendopeptidasesEnzyme InhibitorsSesquiterpenes

Autor:innen und Institutionen

  • Department of Biology Education, Daegu University, 201, Daegudae-ro, Gyeongsan-si 38453, Gyeongsangbuk-do, Republic of Korea.

Zitieren

APA

Moon, D. O. (2024). MetAP2 as a Therapeutic Target for Obesity and Type 2 Diabetes: Structural Insights, Mechanistic Roles, and Inhibitor Development. Biomolecules, 14(12), 1572. https://doi.org/10.3390/biom14121572

Vancouver

Moon DO. MetAP2 as a Therapeutic Target for Obesity and Type 2 Diabetes: Structural Insights, Mechanistic Roles, and Inhibitor Development. Biomolecules. 2024;14(12):1572. doi:10.3390/biom14121572

BibTeX
@article{Moon2024,
  author = {Moon, Dong Oh},
  title = {MetAP2 as a Therapeutic Target for Obesity and Type 2 Diabetes: Structural Insights, Mechanistic Roles, and Inhibitor Development},
  journal = {Biomolecules},
  year = {2024},
  volume = {14},
  number = {12},
  pages = {1572},
  doi = {10.3390/biom14121572}
}
Kostenlos starten →